James Thomas, MD, PhD

Publications

• A Comprehensive Program for the Enhancement of Accrual to Clinical Trials.

  (Porter M, Ramaswamy B, Beisler K, Neki P, Single N, Thomas J, Hofacker J, Caligiuri M, Carson WE 3rd.) Ann Surg Oncol. 2016 07;23(7):2146-52 PMID: 26790668 01/23/2016

• p38γ MAPK is required for inflammation-associated colon tumorigenesis.

  (Yin N, Qi X, Tsai S, Lu Y, Basir Z, Oshima K, Thomas JP, Myers CR, Stoner G, Chen G.) Oncogene. 2016 Feb 25;35(8):1039-48 PMID: 25961922 SCOPUS ID: 2-s2.0-84959509513 05/12/2015

• Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma.

  (Miura JT, Johnston FM, Tsai S, George B, Thomas J, Eastwood D, Banerjee A, Christians KK, Turaga KK, Pawlik TM, Clark Gamblin T.) Ann Surg Oncol. 2015 Oct;22(11):3716-23 PMID: 25777092 SCOPUS ID: 2-s2.0-84941418828 03/18/2015

• Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument.

  (Jayakrishnan TT, Nadeem H, Groeschl RT, George B, Thomas JP, Ritch PS, Christians KK, Tsai S, Evans DB, Pappas SG, Gamblin TC, Turaga KK.) HPB (Oxford). 2015 Feb;17(2):131-9 PMID: 25123702 PMCID: PMC4299387 SCOPUS ID: 2-s2.0-84920841239 08/16/2014

• Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Colorectal Liver Metastases: A Meta-Analysis.

  (Zacharias AJ, Jayakrishnan TT, Rajeev R, Rilling WS, Thomas JP, George B, Johnston FM, Gamblin TC, Turaga KK.) PLoS One. 2015;10(10):e0139940 PMID: 26448327 PMCID: PMC4598149 SCOPUS ID: 2-s2.0-84948706797 10/09/2015

• Tumor profiling of gastric and esophageal carcinoma reveal different treatment options.

  (Miura JT, Xiu J, Thomas J, George B, Carron BR, Tsai S, Johnston FM, Turaga KK, Gamblin TC.) Cancer Biol Ther. 2015;16(5):764-9 PMID: 25778705 PMCID: PMC4622996 SCOPUS ID: 2-s2.0-84943767513 03/18/2015

• Molecular profiling in gastric cancer: examining potential targets for chemotherapy.

  (Miura JT, Johnston FM, Thomas J, George B, Eastwood D, Tsai S, Christians KK, Turaga KK, Gamblin TC.) J Surg Oncol. 2014 Sep;110(3):302-6 PMID: 24844210 SCOPUS ID: 2-s2.0-84905367494 05/23/2014

• Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease.

  (Hwang M, Jayakrishnan TT, Green DE, George B, Thomas JP, Groeschl RT, Erickson B, Pappas SG, Gamblin TC, Turaga KK.) Eur J Cancer. 2014 Jul;50(10):1747-1757 PMID: 24767470 SCOPUS ID: 2-s2.0-84901752316 04/29/2014

• Management of acute cholecystitis in cancer patients: a comparative effectiveness approach.

  (Jayakrishnan TT, Groeschl RT, George B, Thomas JP, Pappas S, Gamblin TC, Turaga KK.) Surg Endosc. 2014 May;28(5):1505-14 PMID: 24687416 SCOPUS ID: 2-s2.0-84900328041 04/02/2014

• Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?

  (Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B.) Oncologist. 2014 Mar;19(3):266-74 PMID: 24569947 PMCID: PMC3958454 SCOPUS ID: 2-s2.0-84896486447 02/27/2014

• 5-FU/leucovorin, uifinotecan, oxaliplatin (FOLFIRINOX)induction followed by chemoXRT in borderline resectable pancreatic cancer.

  (Jordan Kharofa, Tracy R. Kelly, Paul S. Ritch, Ben George, Lauren Allison Wiebe, James P. Thomas, Kathleen K. Christians, Douglas B. Evans, Beth Erickson .) Journal of Clinical Oncology . 10.1200/jco.2012.30.15_suppl.e1461 Journal of Clinical Oncology 30, no. 15_suppl -published online before print 01/09/2018

• PB-42: Design and characterization of a glutathione pro-drug selectively delivered to normal tissue and not tumor tissue

  (Thomas JP, Geiger PG.) Cancer Res. Thomas JP, Geiger PG. Abstract 4443: PB-42: Design and characterization of a glutathione pro-drug selectively delivered to normal tissue and not tumor tissue. Cancer Res. August 1, 2015 75; 4443. 08/01/2015